KPV: Five Studies, Zero Humans, One Consistent Signal

The short version

KPV is a tiny, three-amino-acid peptide (lysine-proline-valine) that corresponds to the tail end of a natural hormone, alpha-melanocyte-stimulating hormone (alpha-MSH). It keeps that hormone's anti-inflammatory activity without the pigment-darkening effect the full hormone has. Almost all of the research on KPV focuses on one place: the gut lining, where it is taken up directly by an intestinal transporter and calms inflammatory signaling in models of colitis. Every study behind that story is preclinical — mice, rats, or human cells in a dish. No published human clinical trial of KPV exists. This page reports exactly what was measured, in which model, at what dose, and leaves it there: no recommended human dose, no medical claim, and no suggestion that a rodent colitis result predicts an outcome in a person.

What it is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine (molecular formula C16H30N4O4), corresponding to residues 11-13 — the C-terminal three amino acids — of alpha-MSH, a 13-residue hormone. Isolating just this tail fragment matters mechanistically: alpha-MSH's melanogenic (pigment-darkening) activity depends on a different part of the molecule, so KPV retains the anti-inflammatory signal while dropping the pigmentary one. As a free tripeptide it is small and peptidase-labile, meaning it breaks down quickly in biological fluids — which is why a large share of the recent published work is formulation science (nanoparticles, hydrogels, targeted delivery systems) aimed at keeping enough intact KPV in contact with inflamed tissue long enough to act, rather than efficacy science testing new indications.

How it works

KPV's defining mechanistic feature is that it is taken up directly into intestinal epithelial cells by PepT1 (gene SLC15A1), a transporter for di- and tripeptides that is upregulated specifically in inflamed gut tissue — meaning KPV concentrates preferentially where the inflammation is. Once inside, nanomolar concentrations of KPV suppress NF-kB and MAP-kinase signaling, two of the central switches that turn on production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha. The net effect in animal colitis models is a calmer inflammatory environment: less cytokine output, less immune-cell infiltration, and, in at least one model, an effect that persisted even in mice lacking the melanocortin-1 receptor — indicating the anti-inflammatory action does not require the classic alpha-MSH receptor pathway and is likely a separate, receptor-independent mechanism.

What the research shows

Nanoparticle co-delivery (2024). A PepT1-targeted nanodrug combining KPV with the immunosuppressant FK506 improved both acute (4% DSS) and chronic (2.5% DSS) colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond either agent given alone ^[6].

Oral hydrogel delivery (2017). Hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue in DSS-induced colitis and reduced disease severity more effectively than non-targeted formulations, with a stronger capacity to prevent mucosal damage and downregulate TNF-alpha ^[7].

Transporter mechanism (2008). In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells, nanomolar KPV inhibited NF-kB and MAP-kinase activation and cytokine secretion; orally administered KPV reduced the severity of both DSS- and TNBS-induced colitis in C57BL/6 mice ^[8].

Receptor-independence (2008). KPV reduced colonic inflammation in DSS-induced and CD45RB-hi adoptive-transfer colitis models, producing earlier recovery, lower myeloperoxidase activity, and reduced inflammatory infiltrate — with the effect retained in MC1R-deficient mice, indicating an MC1R-independent mechanism ^[9].

Broader tripeptide review (2008). A comprehensive review situates KPV within a family of alpha-MSH-derived tripeptides showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic, and organ-injury models, distinguishing it from melanocortin agonists used for pigmentation ^[10].

Reported effects, cautions & safety

KPV does not have the large research-use community that BPC-157 or TB-500 do — it is compounded far less often as a stand-alone injectable, and the online record of self-reported effects is too thin to summarize responsibly here. Rather than manufacture a signal that does not exist, this page draws its cautions from the peer-reviewed literature directly.

The defining caution is the simplest one: no published human clinical trial of KPV exists. Every efficacy claim above comes from a mouse, rat, or cell-culture model — there is no established human dose, no known human pharmacokinetics, and no human safety database to check a reported effect against ^[8][9]. A second, related caution concerns the molecule itself: free KPV is a small, peptidase-labile tripeptide, meaning most of the recent published effort is aimed at keeping it intact long enough to reach inflamed tissue ^[6][7] — a formulation problem that has not been solved for the simple, unformulated peptide many research suppliers sell. Finally, marketing claims for KPV in general wellness contexts (skin, broad anti-inflammatory use) regularly outrun what the cited evidence supports, which remains preclinical and colitis-specific ^[10].

Where it fits in soft-tissue and connective-tissue repair research

KPV occupies a different corner of this desk's frame than GLOW or TB-500: its tissue of interest is the gut mucosa, not skin or tendon, and its mechanism is anti-inflammatory rather than structural or vascular. It belongs on a soft-tissue-repair desk because inflammation control is often the first step that allows structural repair to proceed — the same logic that underlies why BPC-157 (a GLOW constituent) is studied for both gut and connective-tissue healing. Compared with TB-500, which has a 40-person human safety trial behind its parent protein, KPV has none — the widest evidence gap of the three compounds here. See the comparison page for how that gap lines up dimension by dimension.